esis factors. This dose of aspirin was chosen because we originally wanted to study the potential effects of aspirin and EPA + DHA on platelet function [19]. It remains possible that other doses of aspirin, or ingestion of aspirin for longer time points, might affect some of the inflammatory cytokines or proangiogenesis factors measured. Alternatively, while the clearance of many cytokines and angiogenesis factors occurs quickly with half-lives of <3 hours, it is possible that the effects of aspirin on molecules with longer half-lives could be detected in studies with longer periods of aspirin use. In addition, the data in this study should be cautiously interpreted as the number of participants was relatively small. Their age was also quite low and they were quite healthy, limiting the ability to predict the process of atherosclerosis and clinical events. Thus, different results could be found in a much larger cohort with older, or diseased, participants. In addition, we were not able to determine if the angiogenesis stimulating factors of cigarette smoking [20] and endothelial progenitor cells [21] influence the effects that EPA + DHA or aspirin had on the pro-angiogenesis molecules that we measured. Future studies will be needed to investigate these possibilities.

In conclusion, our findings support the idea that the ω3 fatty acids EPA + DHA have anti-inflammatory and anti-angiogenesis effects in vivo, which may contribute to the beneficial effects of fish oil supplementation in susceptible human subjects who take or do not take aspirin.


We are indebted to Mary Rose Burnham, PhD, and Kelly Keating, PhD, of the Albany College of Pharmacy, for their assistance with improving the quality and grammar of the text. We are indebted to Kelly Thevenet-Morrison, MS, of the University of Rochester for her assistance with improving the quality of the figures.


  1. Bonow, R.O., Smaha, L.A., Smith, S.C. Jr, Mensah, G.A. and Lenfant, C. (2002) World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation, 106, 1602- 1605. doi:10.1161/01.CIR.0000035036.22612.2B
  2. Celletti, F.L., Waugh, J.M., Amabile, P.G., Brendolan, A., Hilfiker, P.R. and Dake, M.D. (2001) Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine, 7, 425-429. doi:10.1038/86490
  3. Serhan, C.N., Chiang, N. and Van and Dyke, T.E. (2008) Resolving inflammation: Dual anti-inflammatory and proresolution lipid mediators. Nature Reviews Immunology, 8, 349-361. doi:10.1038/nri2294
  4. Kereiakes, D.J. (2003) Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: The role of modulating inflammation. Circulation, 108, III22-27. doi:10.1161/01.CIR.0000086951.09881.51
  5. Kris-Etherton, P.M., Harris, W.S. and Appel, L.J. (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 106, 2747-2757. doi:10.1161/01.CIR.0000086951.09881.51
  6. Larson, M.K., Ashmore, J.H., Harris, K.A., Vogelaar, J.L., Pottala, J.V., Sprehe, M., et al. (2008) Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost, 100, 634-641.
  7. Coleman, J.L. and Alberts, M.J. (2006) Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. American Journal of Cardiology, 98, 838-841. doi:10.1016/j.amjcard.2006.03.071
  8. Spencer, L., Mann, C., Metcalfe, M., Webb, M., Pollard, C., Spencer, D., et al. (2009) The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. European Journal of Cancer, 45, 2077-2086. doi:10.1016/j.ejca.2009.04.026
  9. Wallace, J.M., McCabe, A.J., Roche, H.M., Higgins, S., Robson, P.J., Gilmore, W.S., et al. (2000) The effect of low-dose fish oil supplementation on serum growth factors in healthy humans. European Journal of Clinical Nutrition, 54, 690-694. doi:10.1038/sj.ejcn.1601076
  10. Baumann, K.H., Hessel, F., Larass, I., Muller, T., Angerer, P., Kiefl, R., et al. (1999) Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thrombosis Vascular Biology, 19, 59-66. doi:10.1161/01.ATV.19.1.59
  11. Calder, P.C. (2006) N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. American Journal of Clinical Nutrition, 83, 1505S-1519S.
  12. Novak, T.E., Babcock, T.A., Jho, D.H., Helton, W.S. and Espat, N.J. (2003) NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNFalpha transcription. American Journal of Physiology Lung Cellular and Molecular Physiology, 284, L84-L89.
  13. Yin, R., Huang, H., Zhang, J., Zhu, J., Jing, H. and Li, Z. (2008) Dietary n-3 fatty acids attenuate cardiac allograft vasculopathy via activating peroxisome proliferator-activated receptor-gamma. Pediatric Transplantation, 12, 550- 556. doi:10.1111/j.1399-3046.2007.00849.x
  14. Kew, S., Mesa, M.D., Tricon, S., Buckley, R., Minihane, A.M. and Yaqoob P. (2004) Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. American Journal of Clinical Nutrition, 79, 674- 681.
  15. Khurana, R., Simons, M., Martin, J.F. and Zachary, I.C. (2005) Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation, 112, 1813-1824. doi:10.1161/CIRCULATIONAHA.105.535294
  16. Simons, M. and Ware, J.A. (2003) Therapeutic angiogenesis in cardiovascular disease. Nature Reviews Drug Discovery, 2, 863-871. doi:10.1038/nrd1226
  17. Connor, K.M., SanGiovanni, J.P., Lofqvist, C., Aderman, C.M., Chen, J., Higuchi, A., et al. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medecine, 13, 868-873. doi:10.1038/nm1591
  18. Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. Journal of Clinical Endocrinology & Metablism, 91, 439-446. doi:10.1210/jc.2005-1303
  19. Patrono, C., Garcia Rodriguez, L.A., Landolfi, R. and Baigent, C. (2005) Low-dose aspirin for the prevention of atherothrombosis. New England Journal of Medecine, 353, 2373-2383. doi:10.1056/NEJMra052717
  20. Dasgupta, P. and Chellappan, S.P. (2006) Nicotine-mediated cell proliferation and angiogenesis: New twists to an old story. Cell Cycle, 5, 2324-2328. doi:10.4161/cc.5.20.3366
  21. Losordo, D.W. and Dimmeler, S. (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II: Cell-based therapies. Circulation, 109, 2692-2697. doi:10.1161/01.CIR.0000128596.49339.05


*Financial Support: this publication was made possible by Grant Number KL2 RR 024136 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at Information on Re-engineering the Clinical Research Enterprise can be obtained from LK is supported through a Canadian Institutes of Health Research (CIHR) grant number: MOP-67121.

Journal Menu >>